- Home
- MDAI vs ALLK Comparison
MDAI vs ALLK Comparison
Compare MDAI & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- ALLK
- Stock Information
- Founded
- MDAI 2013
- ALLK 2012
- Country
- MDAI United States
- ALLK United States
- Employees
- MDAI N/A
- ALLK N/A
- Industry
- MDAI Medical/Dental Instruments
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- ALLK Health Care
- Exchange
- MDAI Nasdaq
- ALLK Nasdaq
- Market Cap
- MDAI 27.8M
- ALLK 23.0M
- IPO Year
- MDAI N/A
- ALLK 2018
- Fundamental
- Price
- MDAI $1.18
- ALLK $0.32
- Analyst Decision
- MDAI Strong Buy
- ALLK Hold
- Analyst Count
- MDAI 2
- ALLK 3
- Target Price
- MDAI $4.75
- ALLK $2.00
- AVG Volume (30 Days)
- MDAI 421.8K
- ALLK 1.8M
- Earning Date
- MDAI 05-06-2025
- ALLK 05-08-2025
- Dividend Yield
- MDAI N/A
- ALLK N/A
- EPS Growth
- MDAI N/A
- ALLK N/A
- EPS
- MDAI N/A
- ALLK N/A
- Revenue
- MDAI $29,581,000.00
- ALLK N/A
- Revenue This Year
- MDAI N/A
- ALLK N/A
- Revenue Next Year
- MDAI $49.47
- ALLK N/A
- P/E Ratio
- MDAI N/A
- ALLK N/A
- Revenue Growth
- MDAI 63.83
- ALLK N/A
- 52 Week Low
- MDAI $0.82
- ALLK $0.22
- 52 Week High
- MDAI $3.25
- ALLK $1.56
- Technical
- Relative Strength Index (RSI)
- MDAI 36.48
- ALLK 59.67
- Support Level
- MDAI $1.04
- ALLK $0.24
- Resistance Level
- MDAI $1.31
- ALLK $0.27
- Average True Range (ATR)
- MDAI 0.14
- ALLK 0.01
- MACD
- MDAI -0.01
- ALLK 0.02
- Stochastic Oscillator
- MDAI 22.49
- ALLK 98.23
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.